So Take­da wants to do up to $20B in M&A? Wel­come to the bid­ding war for US biotechs

Over the past few months Take­da has un­veiled an R&D over­haul that in­cludes a con­cen­tra­tion in key US and Japan­ese hubs and a de­ci­sion to cut and trans­fer 300 staffers to a CRO. Now the Fi­nan­cial Times re­ports that the big Japan­ese phar­ma com­pa­ny is plot­ting to spend any­where from $10 bil­lion to $15 bil­lion or $20 bil­lion on new buy­outs—specif­i­cal­ly fo­cus­ing on the US.

Quot­ing sources who have been briefed on the not-so-se­cret mis­sion, the FT says that this is part of a surge of in­ter­est that Japan­ese phar­ma com­pa­nies like Astel­las and Sh­iono­gi have shown re­cent­ly in join­ing the M&A game. Take­da may split its cash pot in­to sev­er­al deals, or go for one big one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER